

Edgar Filing: GENOMED INC - Form 8-K

GENOMED INC  
Form 8-K  
July 22, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
JULY 19, 2004

GenoMed, INC.  
-----

(Exact name of registrant as specified in its charter)

FLORIDA	000-49720	43-1916702
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS Employer Identification Number)

9666 Olive Blvd., Suite 310, St. Louis, Missouri 63132  
-----

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:  
-----

(314) 652-0500

909 South Taylor Avenue, St. Louis, Missouri 63110  
-----

(Former name or former address if changed since last report)

ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

- (a) On July 19, 2004, the registrant's independent auditor, Stark Winter Schenklin & Co., LLP ("SWS") of Denver, Colorado, was dismissed. The decision to dismiss SWS was approved by the board of directors of the registrant.

For fiscal year 2002, SWS issued a qualified opinion on the registrant's financial statements, expressing "substantial doubt about the Company's ability to continue as a going concern."

For the fiscal year 2003, SWS did not issue an adverse opinion, disclaimer of opinion or modification or qualification of opinion on the registrant's financial statements.

## Edgar Filing: GENOMED INC - Form 8-K

During the two most recent fiscal years of the registrant there has been no disagreement with SWS on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which if not resolved to the satisfaction of SWS, would have caused it to make reference to the subject matter of the disagreement in connection with its report.

The registrant has authorized SWS to respond fully to any inquiries of its new auditor concerning any issue relating to the registrant's accounting principles or practices or financial reporting, the registrant's financial statements or SWS's audit thereof or audit opinions thereon.

The registrant has provided a copy of the disclosures in this report to SWS. Any letter from SWS pursuant to paragraph (a)(3) of Regulation S-K will be supplied by amendment.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

GenoMed, Inc.

Dated: July 22, 2004

By: /S/ David Moskowitz

-----  
Dr. David Moskowitz  
Chairman of the Board and  
Chief Executive Officer